Consensus ResMed, Inc.

Equities

RMD

US7611521078

Market Closed - Nyse Other stock markets 04:00:02 2024-05-17 pm EDT			5-day change	1st Jan Change
218.6 ^USD	-0.64%		+2.22%	+27.06%

May. 14	Transcript : ResMed Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 04:05 PM
May. 10	Resmed Insider Sold Shares Worth $2,747,810, According to a Recent SEC Filing	MT

Evolution of the average Target Price on ResMed, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e0677.xF2f8heZfSxOGWRo4rQ0BvLI5MI8DSYBhoHOPMKqPys.8WrMoX3vGHwAaQ4erN1VZIixoIl5XBJqv-qhTJfJbVORF_KET6hJSilzLQ~f2028d308dda21288dbb999b6ce18228

Analyst Recommendations on ResMed, Inc.

Resmed Insider Sold Shares Worth $2,747,810, According to a Recent SEC Filing	May. 10	MT
Resmed Insider Sold Shares Worth $3,178,815, According to a Recent SEC Filing	May. 09	MT
KeyBanc Adjusts Price Target on ResMed to $238 From $227	Apr. 26	MT
Jefferies Adjusts Price Target on ResMed to $180 From $164	Apr. 26	MT
Oppenheimer Adjusts ResMed Price Target to $200 From $205, Maintains Outperform Rating	Apr. 26	MT
JPMorgan Adjusts Price Target on ResMed to $225 From $198	Apr. 26	MT
Mizuho Adjusts Price Target on ResMed to $220 From $215	Apr. 26	MT
Needham Adjusts Price Target on ResMed to $236 From $224	Apr. 26	MT
Morgan Stanley Adjusts Price Target on ResMed to $219 From $207	Apr. 26	MT
RBC Adjusts Price Target on ResMed to $200 From $187	Apr. 26	MT
Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating	Apr. 01	MT
Morgan Stanley Adjusts Resmed’s Price Target to AU$31.80 From AU$28.60, Keeps at Overweight	Mar. 05	MT
Evans & Partners Upgrades ResMed to Positive From Neutral, Price Target is AU$31	Mar. 04	MT
Powell, the paper tiger	Feb. 05
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking...	Feb. 05
Mizuho Adjusts Price Target on ResMed to $215 From $195, Keeps Buy Rating	Jan. 30	MT
Oppenheimer Raises ResMed Price Target to $205 From $185, Maintains Outperform Rating	Jan. 30	MT
UBS Adjusts ResMed Price Target to $180 From $175, Maintains Neutral Rating	Jan. 25	MT
Oppenheimer Raises ResMed Price Target to $185 From $175, Maintains Outperform Rating	Jan. 25	MT
RBC Lifts Price Target on ResMed to $182 From $181, Cites 'Solid' Fiscal Q2 Results, Keeps Sector Perform Rating	Jan. 25	MT
RBC Cuts Price Target on ResMed to $181 From $200, Keeps Sector Perform Rating	Jan. 22	MT
JPMorgan Adjusts Price Target on ResMed to $195 From $160, Maintains Overweight Rating	Jan. 09	MT
Nvidia comes to Wall Street's rescue	Jan. 09
ANALYST RECOMMENDATIONS : Blackrock, Blackstone, Exxon Mobil, Netflix, Charles Schwab...	Jan. 09
Joe Biden and Xi Jinping almost made up	Nov. 16

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

218.6 USD

Average target price

216.6 USD

Spread / Average Target

-0.88%

High Price Target

264 USD

Spread / Highest target

+20.79%

Low Price Target

180 USD

Spread / Lowest Target

-17.65%

Consensus detail

Consensus revision (last 18 months)

Analysts covering ResMed, Inc.

KeyBanc Capital Markets
Jefferies & Co.
Oppenheimer
JPMorgan Chase
Mizuho Securities
Needham & Co.
Morgan Stanley
RBC Capital Markets
Evans & Partners
UBS
BofA Securities
Wolfe Research
JMP Securities
Citigroup
Goldman Sachs
Baird
Macquarie
J.P. Morgan Chase

Ratings for ResMed, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar